<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687934</url>
  </required_header>
  <id_info>
    <org_study_id>9090-02</org_study_id>
    <secondary_id>9090-02</secondary_id>
    <nct_id>NCT00687934</nct_id>
  </id_info>
  <brief_title>Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synta Pharmaceuticals Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synta Pharmaceuticals Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label dose escalation study of patients with solid tumors treated with STA-9090
      (ganetespib)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities</measure>
    <time_frame>Cycle 1</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Ganetespib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ganetespib once weekly infusion, dose escalation study, with treatment until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STA-9090</intervention_name>
    <description>This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.</description>
    <arm_group_label>Ganetespib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be documented to be refractory or not candidates for current approved
             therapies.

          -  Must have an ECOG status 0-2.

          -  Peripheral neuropathy &lt; or = 2.

          -  Must have acceptable organ and marrow function per protocol parameters.

          -  No clinically significant ventricular arrythmias or ischemia.

        Exclusion Criteria:

          -  Must not be pregnant or breastfeeding.

          -  Chemotherapy or radiation within 3 weeks.

          -  Previous radiation to &gt;25% of total bone marrow.

          -  Previous high dose chemotherapy with autologous or allogeneic hematopoietic stem cell
             transplantation.

          -  Primary brain tumors or active brain metastases.

          -  Use of any investigational agents within 4 weeks.

          -  Treatment with chronic immunosuppressants.

          -  Uncontrolled, intercurrent illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Premiere Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404-2111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology Dayton Oncology and Hematology, P.A</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <last_update_submitted>September 17, 2014</last_update_submitted>
  <last_update_submitted_qc>September 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic cancer</keyword>
  <keyword>solid tumor</keyword>
  <keyword>histologically or cytologically confirmed non-hematological</keyword>
  <keyword>malignancy that is metastatic or unresectable for which no</keyword>
  <keyword>standard therapy exists</keyword>
  <keyword>STA-9090</keyword>
  <keyword>ganetespib</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

